Payne Laboratory - People
Current Lab Members
Kyle Kristopher Payne, PhD – Principle Investigator
Hima Doshi – Administrative Research Associate
Rinkee Kumari, PhD – American Cancer Society Postdoctoral Fellow; Tumor Immunology
Elaheh Hosseini – PhD Student; Cellular and Molecular Pharmacology
Maria Søgaard – PhD Student; Biochemistry
Christopher Alcott – PhD Student; Cellular and Molecular Pharmacology
Hispanic Heritage Month 2022
National Hispanic Heritage Month
If you identify as Hispanic or Latino, what can you do to reduce your cancer risk? Evelyn Fuertes, BA, NDTR, shares evidence-based cancer information with this population and steps that can be taken now to prevent and reduce risk of disease. Learn more
RUF September-October Campaign 2022
Help Save Lives All Year Long
When you become a monthly, sustaining donor, your partnership helps power the research and clinical trials that help save lives. #StayInTheFight
Survivorship Wellness Lecture Series
.divTable {
display: table;
width: 100%;
}
.divTableRow {
display: table-row;
}
.divTableHeading {
background-color: #EEE;
display: table-header-group;
}
.divTableCell,
.divTableHead {
display: table-cell;
height: auto;
width: 50%;
}
.divTableBody {
display: table-row-group;
}
The Cancer Survivorship Wellness Program at Rutgers Cancer Institute is dedicated to easing th
A Commitment to Diversity and Inclusivity in Cancer Clinical Trials
Clinical trials evaluate the efficacy, safety, and effectiveness of clinical treatments and devices, including drugs, surgeries, diets, behavioral approaches, and lifestyle interventions seeking to improve individual and community health. To account for the diverse lived experiences and exposures of various populations, clinical trials must be appropriately inclusive of racial and ethnic minority groups, as well as other populations experiencing health disparities, including sexual and gender minority or socioeconomically disadvantaged populations.
Cole Laboratory
Pediatric Cancer Research Lab
Research and Current Funding
Brain dysfunction is one example of chemotherapy-related toxicity that can affect children with cancer during, and long after, curative treatment. Survivors of childhood cancer are more likely than people who were never treated for cancer to exhibit decreased attention span, poor working memory, and problems with executive functions like cognitive flexibility and task shifting, impulse control, planning, focusing attention, and remembering complex instructions.